P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 3, 2003, Pages 683-692

  Hammond, Elizabeth ^a   Berkey, Brian A ^b   Fu, Karen K ^c   Trotti, Andy ^d   Meredith, Ruby F ⁱ   Jones, Christopher U ^e   Byhardt, R ^f   Horwitz, E M ^g   Ang, K Kian ^h  

^a LDS HOSPITAL   (United States)

^b RTOG Statistical Unit   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e Radiation Oncology Center   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ LDS Hospital ^*

Author keywords

Head and neck cancer; p105; Proliferation; Radiotherapy

Indexed keywords

ANTIBODIES; ANTIGENS; BIOPSY; CELLS; DNA; RADIOTHERAPY; TUMORS;

ANTIGEN DENSITY (AD);

ONCOLOGY;

CELL NUCLEUS ANTIGEN; DNA; PARAFFIN; PROTEIN ANTIBODY; PROTEIN P105;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FRACTIONATION; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX CANCER; LABELING INDEX; LABORATORY; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIVARIATE ANALYSIS; OROPHARYNX CANCER; PHASE 3 CLINICAL TRIAL; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STAINING; SUSPENSION; TONGUE CANCER; TUMOR BIOPSY; TUMOR CELL CULTURE;

EID: 0141615694     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00642-4     Document Type: Article

References (31)

1. Clevenger C.V., Epstein A.L. Identification of a nuclear protein component of interchromatin granules using a monoclonal antibody and immunogold electron microscopy. Exp Cell Res. 151:1984;194-207.
2. Fu K.K., Hammond E., Pajak T.F., et al. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers Results of RTOG 91-08 . Int J Radiat Oncol Biol Phys. 29:1994;661-671.
3. Fu K.K., Pajak T.F., Trotti A., et al. Phase III randomized study to compare hyperfractionation and 2 variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas First report of RTOG 9003 . Int J Radiat Oncol Biol Phys. 48:2000;7-16.
4. Wilcoxon F. Individual comparison by ranking methods. Biometrics. 1:1945;80-83.
5. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
6. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980. p. 163-178.
7. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chem Rep. 5:1966;163-170.
8. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154.
9. Cox D.R. Regression models and life tables. J R Stat Soc Series B. 34:1972;187-229.
10. Appley A.J., Fitzgibbons P.L., Chandrasoma P.T., Hinton D.R., Apuzzo M.L.J. Multiparameter flow cytometric analysis of neoplasms of the central nervous system Correlation of nuclear antigen p105 and DNA content with clinical behavior . Neurosurgery. 27:1990;83-96.
11. Fitzgibbons P.L., Appley A.J., Turner R.R., et al. Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer. 62:1988;1556-1560.
12. Kimura H., Yonemura Y., Epstein A.L. Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in advanced gastric cancers. Cancer. 68:1991;2175-2180.
13. Ohyama S., Yonemura Y., Kimura H., Kosaka T., Miyazaki I., Sasaki T. Proliferation-associated nuclear antigen p105 as a marker for metastasis of human gastric cancer. J Cancer Res Clin Oncol. 117:1991;583-586.
14. Turner R.R., Layfield L.J., Bishop P.C., Epstein A., Parker J.W. Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas. Arch Pathol Lab Med. 113:1989;907-911.
15. Yokogi H. Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma. Cancer. 78:1996;819-826.
16. Demirer T., Uzunalimoglu O., Anderson T., et al. Flow cytometric measurement of proliferation-associated nuclear antigen P105 and DNA content in immuno-proliferative small intestinal disease (IPSID). J Surg Oncol. 58:1995;25-30.
17. Oka K., Nakano T., Arai T. Cytoplasmic p105 index is an accurate mitotic index, but is not related to prognosis in cervical carcinoma. Arch Pathol Lab Med. 118:1994;506-509.
18. Appley A.J., Fitzgibbons P.L., Chandrasoma P.T., Hinton D.R., Apuzzo M.L. Multiparameter flow cytometric analysis of neoplasms of the central nervous system Correlation of nuclear antigen p105 and DNA content with clinical behavior . Neurosurgery. 27:1990;83-96.
19. Turner R.R., Layfield L.J., Bishop P.C., Epstein A.L., Parker J.W. Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas. Arch Pathol Laboratory Med. 113:1989;907-911.
20. Ang K.K., Berkey B., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62:2002;7350-7356.
21. Ang KK, Berkey BA, Koki AT, et al. Prognostic significance of COX-2 expression in advanced head and neck cancer treated with radiotherapy in a Phase III RTOG trial (90-03). Eur J Cancer 2001;37:S37.
22. st Annual Meeting of the American Association of Cancer Research. 2000;43:S802.
23. Calvin D.P., Berkey B.A., Pajak T.F., et al. Microvessel density (MVD) ≥ 60 does not predict for outcome in advanced head and neck squamous cell carcinoma Results of a prospective study from the RTOG 90-03 trial . Int J Radiat Oncol Biol Phys. 51:2001;41.
24. Cullen KJ, Hussein MR. Predictors of response to chemotherapy and radiotherapy in head and neck cancer. Updates ofHead and Neck Cancer: A Multidisciplinary Approach 2002;2:1-11.
25. Corvo R., Antognoni P., Sanguineti G. Biologic predictors of response to radiotherapy in head and neck cancer Recent advances and emerging perspectives . Tumori. 87:2001;355-363.
26. Quon H., Liu F.F., Cummings B.J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck. 23:2001;147-159.
27. Smith B.D., Haffty B.G., Sasaki C.T. Molecular markers in head and neck squamous cell carcinoma Their biologic function and prognostic significance . Ann Otol Rhinol Laryngol. 110:2001;221-228.
28. Mohr S., Leikauf G.D., Keith G., Rihn B.H. Microarrays as cancer keys An array of possibilities . J Clin Oncol. 20:2002;3165-3175.
29. Macgregor P.F., Squire J.A. Application of microarrays to the analysis of gene expression in cancer. Clin Chem. 48:2002;1170-1177.
30. Belbin T.J., Singh B., Barber I., et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res. 62:2002;1184-1190.
31. Skacel M., Skilton B., Pettay J.D., Tubbs R.R. Tissue microarrays A powerful tool for high-throughput analysis of clinical specimens: A review of the method with validation data . Appl Immunohistochem Mol Morphol. 10:2002;1-6.